Peak Bio, Inc. announced that it has entered into a securities purchase agreement to issue convertible note on December 18, 2023. The company may close the transaction in one or two tranches. The company shall, at each closing of the offering of the Convertible Notes, pay a cash commission equal to 8% of the gross proceeds received by the Company from Qualified Investors from such closing.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0096 USD | +11.63% |
|
+11.63% | -94.88% |
25/06 | Peak Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
28/05 | Peak Bio, Inc. announced that it has received $1.3245 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-94.88% | 222K | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.31% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. announced a financing transaction